Document Detail

Novel Direct-Acting Anticoagulants for Risk Reduction in ACS.
MedLine Citation:
PMID:  23172897     Owner:  NLM     Status:  Publisher    
Approximately 1.2 million people are hospitalized annually for acute coronary syndrome (ACS) in the United States, with direct medical costs estimated at $150 billion in 2009. Rehospitalization is common, often as the result of recurrence of the initial event or complications of ACS or its therapy. Thrombosis is central to the pathogenesis of ACS. The current standard of care includes dual antiplatelet therapy, which reduces platelet activation and aggregation, integral steps for forming a thrombus. However, antiplatelet therapy does not prevent continued thrombin generation or the deposition of fibrin in the clot and residual risk of a recurrent event remains high. New oral anticoagulants offer a mechanism of action that is different from and complementary to that of antiplatelet agents. The ATLAS ACS-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial, using rivaroxaban, is the first trial of the new oral anticoagulants to show a benefit when added to antiplatelet therapy in reducing ACS events and mortality. While there was more major bleeding with the addition of rivaroxaban, fatal bleeding was not increased. These agents, if added to the current standard of care, might substantially reduce the high clinical and economic consequences of ACS.
Paul P Dobesh; Julie H Oestreich
Related Documents :
25348157 - Impact of remote ischemic preconditioning preceding coronary artery bypass grafting on ...
20952767 - Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular func...
18364707 - Aortic regurgitation: disease progression and management.
14529587 - Possible involvement of apoptotic death of myocytes in left ventricular remodeling afte...
18805117 - Influence of left atrial and ventricular volumes on the relation between mitral valve a...
8945687 - The role of protein kinase in c ischemic/reperfused preconditioned isolated rat hearts.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-19
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  -     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Optimizing Transition of Care Through the Facilitation of a Pharmacist-Managed Deep Vein Thrombosis ...
Next Document:  Compliance With Inpatient Drug Use Process Steps: A Cross-Sectional Observational Study.